VASTox joins European research consortium to target the development of new treatments for cancer
Research will focus on Cancer Stem Cells as target for new therapies
VASTox will work in partnership with five leading research organisations from across Europe to develop treatments that target cancer stem cells (CSCs). In recent years, CSCs have been identified as being an important factor in cancer due to their ability to both initiate and sustain tumour growth. However, there is currently no specific treatment that targets CSCs. The consortium's research will aim to identify the CSCs that cause tumour growth, and thereby generate new drug targets with the ultimate objective of developing new cancer therapies.
The consortium will be coordinated by the European Molecular Biology Laboratory (EMBL) Unit in Italy and includes the University of Lund in Sweden, Cancer Research UK, the UK Medical Research Council, Oxford University and the University of Copenhagen. Initial research will be focused on two types of cancer: leukaemia and breast cancer. The grant is spread over three years and will be split between the consortium members.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.